]> 2026-04-12T03:48:37-07:00 Vitamin D 0 en A toxicity level of 2 for this treatment implies that it has a low toxicity level, meaning the common side effects observed are generally mild and tolerable. The main known side effect is a condition called Hypercalcemia, which is an excessive level of calcium in your blood, that occurs only at high doses of one type of Vitamin D variant. But, it's essential to follow recommended dosage and supplementation strategies for the best therapeutic benefits. The treatment lacks FDA approval currently, hence, it's important to have a conversation with your healthcare provider before starting any new supplement or treatment. 2025-01-18T07:55:14Z 2460693.8300232 Vitamin D 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Numerous laboratory studies have shown that Vitamin D is highly cytotoxic to cancer\ncells, due to several different mechanisms (although labeled as a vitamin it more properly\nshould be considered a hormone). While most research has focused on its ability to\nactivate genes that cause cancer cells to differentiate into mature cells, other effects have\nalso been identified, including cell cycle regulation, inhibition of the insulin-like growth\nfactor, and the inhibition of angiogenesis (246). However, the calcitriol form of Vitamin\nDis not readily usable for cancer treatments because the dosages producing anti-cancer\neffects also cause hypercalcemia, which can be life threatening (the major function of\nVitamin D is to regulate calcium absorption and resorption from the bones and teeth).\nBut like many vitamins\/hormones, the generic designation refers not to a specific\nchemical structure but to a family of related molecules that may have different properties\nof various sorts. For Vitamin D several of these variants (commonly referred to as\nanalogues) have been shown to effectively inhibit cancer cell growth but without the\nsame degree of toxic hypercalcemia. In a 2002 paper in the Journal of Neuro-oncology\n(247), 10 patients with glioblastoma and one with a grade III AA tumor received a form\nof Vitamin D called alfacalcidol in a dosage of .o4 micrograms\/kg each day, a dosage\nthat produced no significant hypercalcemia. The median survival was 21 months, and\nthree of the eleven were long-term survivors (greater than 5 years). Although the\npercentage of patients who responded to the treatment was not high, the fact that any\nrelatively non-toxic treatment can produce any number of long-term survivors is\nremarkable. There is also strong reason to believe that Vitamin D is synergistic with\nretinoids such as accutane (248). Its effectiveness is also increased in the presence of\ndexamethasone (249) and a variety of anti-oxidants, notably carnosic acid, but also\nlycopene, curcumin, silibinin, and selenium (250).\n\nAlfacalcidol is not available in the USA, but is available in Europe and Canada. For those\nin the USA it is possible obtain it from various online marketers. It also should be noted\nthat several other Vitamin D analogues are available, which also have much reduced\nhypercalcemic effects. One of these, paricalcitol, was developed for treatment of a\ndisorder of the parathyroid gland, and recently has been the subject of several\nexperimental studies (251, 252, 253) that have shown it to be highly cytotoxic to\n34\n\nmany different types of cancer. Given that other forms of Vitamin D have been shown to\nbe highly cytotoxic to for glioblastoma cells, and that glioma cells are known to have\nreceptors for Vitamin D, it seems likely that paricalcitol should have efficacy for\nglioblastoma as well. Unfortunately, its routine use is complicated by the fact it is\navailable only in a form that requires intravenous injection.\n\nThe most common version of Vitamin D3 found in health food stores is cholecalciferol,\nwhich is the precursor of calcitriol, the form of Vitamin D utilized by the body. A recent\nstudy of cholecalciferol with prostate cancer patients who had progressed after standard\ntherapy (254) suggests that this common form of Vitamin D3 may be clinically\nbeneficial. Fifteen patients who had failed standard treatments were given 2000 I.U.\ndaily. PSA levels were reduced or stayed the same for nine patients, and there was a\nreliable decrease in the rate of PSA increase for the remainder. No side effects of the\ntreatment were reported by any of the patients.\n\nBecause serum Vitamin D levels have recently been shown to be inversely related to\ncancer incidence, there recently has been considerable discussion about the dosage that is\ntoxic. Doses as high as 5000-10,000 I.U. per day appear to be safe. Recently, it has\nbecome common for women suffering from osteoporosis with low Vitamin D levels to be\ngiven as much as 50,000, I.U.\/day for short time periods. Nevertheless, it is important to\nnote that all forms of Vitamin D can occasionally produce dangerous serum calcium\nlevels, in part because there is a great deal of variability in their effects across individuals.\nIt is thus important that blood calcium levels be monitored, especially while a nontoxic\ndosage is being established."] Vitamin D# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name